Open Access
Issue
Published:
02 June 2022
Tocilizumab in severe COVID-19 – A randomized, double-blind, placebo-controlled trial
Download citation
622
Views
42
Downloads
1
Crossref
N/A
WoS
1
Scopus
N/A
CSCD
The therapeutic effectiveness of interleukin-6 receptor inhibitor in critically ill hospitalized patients with coronavirus disease 2019 (COVID-19) is uncertain.
To evaluate the efficacy and safety of the outcome as recovery or death of tocilizumab for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, we conducted a randomized, double-blinded, placebo-controlled phase 2 trial in critically ill COVID-19 adult patients. The patients were randomly assigned in a 4:1 ratio to receive standard medical treatment plus the recommended dose of either tocilizumab or the placebo drug. Randomization was stratified. The primary outcome was the recovery or death after administration of tocilizumab or a placebo drug. The secondary outcomes were clinical recovery or worsening of the patients' symptoms and inflammatory markers and discharge from the hospital.
Of 190 patients included in this study, 152 received tocilizumab, and 38 received a placebo. The duration of hospital stay of the interventional group was 12.9 ± 9.2, while the placebo group had a more extended hospital stay (15.6 ± 8.8). The mortality ratio for the primary outcome, ie, mortality or recovery in the tocilizumab group was 17.8%; p = 0.58 by log-rank test). The mortality ratio in the placebo group was 76.3%; p = 0.32 by log-rank test). The inflammatory markers in the tocilizumab group significantly declined by day 16 compared to the placebo group.
The use of tocilizumab was associated with decreased mortality, earlier improvement of inflammatory markers, and reduced hospital stay in patients with severe COVID-19.
menu
Tocilizumab in severe COVID-19 – A randomized, double-blind, placebo-controlled trial
Abstract
The therapeutic effectiveness of interleukin-6 receptor inhibitor in critically ill hospitalized patients with coronavirus disease 2019 (COVID-19) is uncertain.
To evaluate the efficacy and safety of the outcome as recovery or death of tocilizumab for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, we conducted a randomized, double-blinded, placebo-controlled phase 2 trial in critically ill COVID-19 adult patients. The patients were randomly assigned in a 4:1 ratio to receive standard medical treatment plus the recommended dose of either tocilizumab or the placebo drug. Randomization was stratified. The primary outcome was the recovery or death after administration of tocilizumab or a placebo drug. The secondary outcomes were clinical recovery or worsening of the patients' symptoms and inflammatory markers and discharge from the hospital.
Of 190 patients included in this study, 152 received tocilizumab, and 38 received a placebo. The duration of hospital stay of the interventional group was 12.9 ± 9.2, while the placebo group had a more extended hospital stay (15.6 ± 8.8). The mortality ratio for the primary outcome, ie, mortality or recovery in the tocilizumab group was 17.8%; p = 0.58 by log-rank test). The mortality ratio in the placebo group was 76.3%; p = 0.32 by log-rank test). The inflammatory markers in the tocilizumab group significantly declined by day 16 compared to the placebo group.
The use of tocilizumab was associated with decreased mortality, earlier improvement of inflammatory markers, and reduced hospital stay in patients with severe COVID-19.
References(22)
M.J. Tahir, M. Saqlain, W. Tariq, et al., Population preferences and attitudes towards COVID-19 vaccination: a cross-sectional study from Pakistan, BMC Public Health 21 (1) (2021) 1759.
Z. Zheng, F. Peng, B. Xu, et al., Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis, J. Infect. 81 (2) (2020) e16–e25.
G. Grasselli, A. Zangrillo, A. Zanella, et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. Jama. 323 (16) (2020) 1574–1581.
D. Wichmann, J.P. Sperhake, M. Lütgehetmann, et al., Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study, Ann. Intern. Med. 173 (4) (2020) 268–277.
G.V. Soraya, Z.S. Ulhaq, Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis, Med. Clin. (Barc) 155 (4) (2020) 143–151.
J. Radbel, N. Narayanan, P.J. Bhatt, Use of Tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report, Chest 158 (1) (2020) e15–e19.
B. Liu, M. Li, Z. Zhou, et al., Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J. Autoimmun. 111 (2020) 102452.
L.A. Henderson, S.W. Canna, G.S. Schulert, et al., On the alert for cytokine storm: immunopathology in COVID-19, Arthritis Rheumatol. Hoboken, NJ 72 (7) (2020) 1059–1063.
G. Navarro, S. Taroumian, N. Barroso, et al., Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums, Semin. Arthritis Rheum 43 (4) (2014) 458–469.
X. Chen, B. Zhao, Y. Qu, et al., Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019, Clin. Infect. Dis 71 (8) (2020) 1937–1942.
R.Q. Le, L. Li, W. Yuan, et al., FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome, Oncologist 23 (8) (2018) 943–947.
R.M. Petrak, N.W. Van Hise, N.C. Skorodin, et al., Early tocilizumab dosing is associated with improved survival in critically ill patients infected with severe acute respiratory syndrome coronavirus-2, Crit. Care Explor 3 (4) (2021) e0395.
S.K. Alzghari, V.S. Acuña, Supportive treatment with tocilizumab for COVID-19: a systematic review, J. Clin. Virol. 127 (2020) 104380.
N. Zhang, X. Xu, L.Y. Zhou, et al., Clinical characteristics and chest CT imaging features of critically ill COVID-19 patients, Eur. Radiol. 30 (11) (2020) 6151–6160.
K.L. Zheng, Y. Xu, Y.F. Guo, et al., Efficacy and safety of tocilizumab in COVID-19 patients, Aging (Albany NY) 12 (19) (2020) 18878.
X. Xu, M. Han, T. Li, et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proc. Natl. Acad. Sci. U. S. A. 117 (20) (2020) 10970–10975.
G. Guaraldi, M. Meschiari, A. Cozzi-Lepri, et al., Tocilizumab in patients with severe COVID-19: a retrospective cohort study, Lancet Rheumatol 2 (8) (2020) e474–e484 Epub 2020 Jun 24. Erratum in: Lancet Rheumatol. 2020;2(10): e591.
E. Moreno-García, V. Rico, L. Albiach, et al., Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection, Rev. Española Quimioterapia 34 (3) (2021) 238.
S. Graupensperger, A.J. Benson, J.R. Kilmer, et al., Social (Un)distancing: teammate interactions, athletic identity, and mental health of student-athletes during the COVID-19 pandemic, J. Adolesc. Health 67 (5) (2020) 662–670.
Publication history
Copyright
Acknowledgements
All authors thank the doctors who participated in this study and helped collect and analyze data.
Rights and permissions
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
FEEDBACK 
TOP